M.M. Dillon & Co.

M.M. Dillon & Co. is a boutique investment bank founded in 2004 and headquartered in Greenwich, Connecticut. The firm specializes in serving healthcare and technology companies, with particular focus on biotech, biopharma, specialty pharma, medical devices, and healthcare software. The firm's ten partners bring extensive C-Suite operating experience, collectively holding over two dozen CEO, CFO, and COO positions alongside more than three dozen board roles.

The firm's partners come from leading institutions including Goldman Sachs, Morgan Stanley, JP Morgan, Credit Suisse, and Citigroup. M.M. Dillon distinguishes itself through its combination of transaction execution capabilities and hands-on corporate sector experience. The firm maintains relationships across hedge funds, private equity, venture capital, public markets, and high-net-worth family offices through its partnership with Brookline Capital Markets.

Since inception, M.M. Dillon has completed over 130 transactions, raising more than $3.5 billion in capital and advising on over $4 billion in deals. The firm's transaction experience spans M&A advisory, capital raising, restructuring, and spin-off transactions across public and private healthcare and technology companies.

Choose M.M. Dillon when you need investment banking services combined with genuine operating expertise in healthcare. The firm's partners have actually run healthcare companies as executives and board members, providing perspective beyond typical financial advisory. This operating knowledge proves particularly valuable in complex biotech M&A, specialty pharma transactions, and medical device financings where understanding the business model is critical to deal success.

Expect senior partner involvement throughout the engagement, with direct access to professionals who have executed hundreds of healthcare transactions. The firm's principal investing approach means they often hold equity positions alongside clients, ensuring aligned incentives for deal execution and long-term value creation.

M.M. Dillon has focused on healthcare investment banking since its founding in 2004, with approximately 60-70% of the firm's business concentrated in healthcare sectors. The firm specializes in biotech, biopharma, specialty pharma, and medical devices, serving both public and private companies across these verticals.

The firm's healthcare expertise is reinforced by partners' operating experience in pharmaceutical and biotechnology companies, including CEO and CFO roles at healthcare corporations. This sector knowledge extends to relationships with healthcare-focused hedge funds, private equity firms, and venture capital investors, particularly given the firm's Greenwich, Connecticut location near major healthcare investment funds.

Ideal clients are biotech, biopharma, specialty pharma, or medical device companies at growth or mature stages requiring M&A advisory, capital raising above $10 million, restructuring guidance, or complex corporate transactions like spin-offs. Companies backed by private equity or venture capital seeking senior-level advisory with deep healthcare operating knowledge will find the firm's approach particularly valuable.